Abbott Receives FDA Approval For ALK Gene Test For Lung Cancer Therapy Selection

Links shared publicly online about this topic.

42
total visits

Abbott Receives FDA Approval For ALK Gene Test For Lung Cancer Therapy Selection

Abbott (NYSE: ABT) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic

View full resource at medicalnewstoday.com

Tags: Genetic, Cancer, Lung Cancer, Lung, Genes, FDA, Genetics

Most Recently Shared on August 29, 2011 at 9:16 pm By:

Roger D. Jones, PhD

Abbott Receives FDA Approval For ALK Gene Test For Lung Cancer Therapy Selection http://t.co/3tptFlu via @mnt_lungcancer #health #medicine

8 months ago...

Retweet

Favorite

Also Shared By:

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

news-medical.net — “Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.” View full resource at news-medical.net